Clinical trials: Safety Study
Drug Safety
A Study to Assess the Efficacy and Safety of Fospropofol Disodium
The aim of this study was to evaluate the pharmacodynamics, safety, and tolerability of Fospropofol disodium up to a dose producing maximal hypnotic effect as defined by electroencephalogramderived assessment (Bispectral Index…
- Trial name
- NCT01271569
- Testing
- Fospropofol disodium
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Safety
Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers
This is a randomised, double-blind, group-sequential, placebo-controlled, safety and pharmacokinetic study in healthy, aged volunteers. Objectives: 1.
- Trial name
- NCT01269476
- Testing
- SNX-001
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- SeneXta Therapeutics SA
Safety
A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers
K-252a is a potent inhibitor of nerve growth factor (NGF) and therefore has the ability to inhibit keratinocyte proliferation. K-252a is strongly lipophilic and therefore passes freely into the cell membranes of keratinocytes and…
- Trial name
- NCT01243502
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Creabilis SA
Safety and Tolerability of SENSIMED Triggerfish in Glaucoma Patients
SENSIMED Triggerfish Discomfort During IOP Monitoring
Evaluation of the wearing discomfort (safety and tolerability) involved during IOP monitoring with the SENISMED Triggerfish, a sensor embedded in a telemetric contact lens
- Trial name
- 09/02 (NCT00966108)
- Testing
- SENSIMED Triggerfish
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sensimed AG
Healthy, Safety
AZD2624 Multiple Ascending Dose Study in Japan
This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624
- Trial name
- JMAD (NCT00696865)
- Testing
- AZD2624
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Vasomotor Symptoms, Endometrial Safety
Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
This pilot study was designed to explore the effects of combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day on the number of vasomotor episodes (hot flashes plus night sweats) in postmenopausal women…
- Trial name
- NCT00332553
- Testing
- Raloxifene, medroxyprogesterone acetate, estrogen
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company